VA119-16-D-0043-000.docx

VHAPM Part 808.405-6 Limiting Sources Attachment 1: Justification for Limiting Sources for Micro-Purchase Threshold up to $150K

FedBizOpps Justification and Approval Notice

CLASSIFICATION CODE

SUBJECT

CONTRACTING OFFICE'S

ZIP-CODE

SOLICITATION NUMBER

BASE NOTICE TYPE

(Required when using Statutory Authority FAR 6.302-1(c))

ARCHIVE

DAYS AFTER THE POSTING DATE

RECOVERY ACT FUNDS

NAICS CODE

SET-ASIDE

CONTRACTING OFFICE

ADDRESS

DESCRIPTION

See Attachment

POINT OF CONTACT

(POC Information Automatically Filled from User Profile Unless Entered)

STATUTORY AUTHORITY

AWARD NUMBER

(Not required when using Statutory Authority FAR 6.302-1(c))

MODIFICATION NUMBER

AWARD AMOUNT

LINE ITEM NUMBER

AWARD DATE (MM-DD-YYYY)

(Not required when using Statutory Authority FAR 6.302-1(c))

AWARDEE NAME

AWARDEE ADDRESS LINE 1

AWARDEE ADDRESS LINE 2

AWARDEE ADDRESS LINE 3

AWARDEE ADDRESS LINE 4

AWARDEE CITY

AWARDEE STATE

AWARDEE ZIP CODE

AGENCY'S URL

URL DESCRIPTION

AGENCY CONTACT'S EMAIL

ADDRESS

EMAIL DESCRIPTION

AWARD INFORMATION

ADDITIONAL INFORMATION

GENERAL INFORMATION

* = Required Field FedBizOpps Justification and Approval Notice Rev. March 2010 Limited Source Justification

583-18-2-943-3048 - STRATTICE MESH

48105 N 339113 Department of Veterans Affairs Ann Arbor Healthcare System Network Contracting Office 10 2215 Fuller Road Ann Arbor MI 48105 Michele R. Bartelt, Contracting Officer Michele.Bartelt@va.gov

FAR 6.302-1

VA119-16-D-0043 36C25018N1950

$29,351.68 03-27-2018

ACADEMY MEDICAL, L.L.C.

380 Columbia Drive Suite 100 West Palm Beach

FL

33409

DEPARTMENT OF VETERANS AFFAIRS

FAR 8 – Justification for Limiting Sources (LSJ) For Limiting Sources (<$150K)

Acquisition Plan Action ID: VA250-18-AP-6852

1. Contracting Activity: Department of Veterans Affairs, VISN 10, Richard L. Roudebush VA Medical Center, 1481 W. 10th Street, Indianapolis, IN 46202 submitted Purchase Request Number: 583-18-2-943-3048.

2. Description of Action: New Requirement, Firm Fixed Price Procurement

Order against: |X| FSS Contract Number: VA119-16-D-0043

3. Description of Supplies or Services:

The estimated value of the proposed action is $29,351.68

One (1) Each, Mesh, Surgical, Reconstructive Tissue Matrix, Porcine Derived, Ster (MPN): 2025002 and One (1) Each, Mesh, Strattice 16 x 20 (MPN): 1620002

The item is required to be delivered on or before March 30, 2018

4. Authority:

ORDER AGAINST FSS: Authority of the Multiple Award Schedule Program, Title III of the Federal Property and Administrative Services Act of 1949 (41 USC 251, et seq.); Title 40 USC 501, Services for Executive Agencies; and Section 803 of the National Defense Authorization Act of 2002 (PL 107-107) and implemented by FAR 8.405-6. Mark the applicable exception:

|_| An urgent and compelling need exists, and following the procedures would result in unacceptable delays(FAR 8.405-6(a)(1)(i)(A);

|X| Only one source is capable of providing the supplies or services required at the level of quality required because the supplies or services are unique or highly specialized; (FAR 8.405-6(a)(1)(i)(B));

|_| In the interest of economy and efficiency, the new work is a logical follow-on to an original Federal Supply Schedule order and the original order was placed in accordance with the applicable Federal Supply Schedule ordering procedures. The original order was not previously issued under sole-source or limited-sources procedures (FAR 8.405-6(a)(1)(i)(C)); or

|_| Items peculiar to one manufacturer. An item peculiar to one manufacturer can be a particular brand name, product, or a feature of a product, peculiar to one manufacturer). A brand name item, whether available on one or more schedule contracts, is an item peculiar to one manufacturer (FAR 8.405-6(b)).

5. Rational/explanation to support cited authority:

INTEGRA™ Bilayer Wound Matrix is an advanced wound care device comprised of a porous matrix of cross-linked bovine tendon collagen and glycosaminoglycan and a semi-permeable polysiloxane (silicone layer). The semi-permeable silicone membrane controls water vapor loss, provides a flexible adherent covering for the wound surface and adds increased tear strength to the device. The collagen-glycosaminoglycan biodegradable matrix provides a scaffold for cellular invasion and capillary growth.

When INTEGRA™ Bilayer Wound Matrix is placed on a surgically debrided or excised wound, it provides the needed framework for the blood vessels and dermal skin cells to remodel the damaged site. As skin cells migrate into the matrix, the collagen is slowly absorbed into the body and replaced with protein that is naturally produced by the skin. In approximately 14 to 21 days, the scaffold is eventually remodeled as the patient’s cells rebuild the damaged site and the silicone layer is removed.

Complete wound closure occurs as epidermal cells migrate from the wound edges. For larger wounds, a thin skin graft of the person’s epidermis may be applied to the wound area to facilitate complete wound closure. Wound closure is typically complete within 30 days. A person is left with a healed wound created from their own tissue. This prevents additional surgeries for the patient and increased recovery times. This is a special/emergent procurement.

6. BRAND NAME ONLY: This buy is estimated to exceed $25,000 and this documentation will be posted along with the RFQ on e-Buy, as required by FAR 8.405-1(e).

7. Note that this determination satisfies the requirements of FAR 8.405-6. The requirement to prepare a written justification IAW FAR 6.303 does not apply to Federal Supply Schedules.

Michele R. Bartelt Contracting Officer Date: March 27, 2018 VHAPM Part 808.405-6 Limiting Sources Page 5 of 5 Original Date: 08/30/2017